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 pROTECTING 
pUBLIC
HEALTH
 the role of penn vet
The community as a whole 
has a stake in environmental 
protection, hygiene and 
sanitation, clean air and 
surface water, uncontaminated 
food and drinking water, 
safe roads and products and 
control of infectious disease.
lawrence o. gostin, public Health 
Law: power | Duty | Restraint
‘‘
Expanding the idea of what a 
veterinary school does to protect 
human and animal health 
BY KELLY STRATTON
in a continuing series of answering the question “What does a veterinarian do?” we focus this issue on three researchers at Penn Vet who are examining big-picture issues with the aim to find solutions for both human kind 
and animal kind. While two of our faculty members featured 
are not trained as veterinarians, their work speaks to the role 
of the veterinary school – and illustrates how Penn Vet is 
uniquely positioned to address such public health issues.
rAbies: A Model Virus
Ronald N. Harty, PhD, associate professor of microbiology, 
takes rabies seriously. Very seriously.
It’s in his lab where he and his team work to better 
understand the virus, focusing on its individual proteins, with 
the ultimate goal of intercepting its budding activities. 
While lab workers don’t work with the live virus – 
instead they use Vesicular Stomatitis Virus (VSV) – this 
pathogen’s proteins act similarly to those of rabies virus. 
Researchers in Dr. Harty’s lab are most interested in the 
molecular events that lead to virus assembly and budding and 
focus on the viral matrix proteins (M proteins) that serve as 
the building blocks of the virus particle. It’s those M proteins 
that work to orchestrate the function of assembly and 
budding and therefore spread of the virus within a body. 
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In addition to studying the relationship between how 
these viral M proteins interact with host proteins to facilitate 
the budding process, Dr. Harty’s lab is also interested in 
understanding the host’s innate immune response to virus 
infection and identifying antivirals that can inhibit the spread 
of the virus. 
“Host proteins are hijacked by the virus to help with 
budding,” said Dr. Harty. “But if we find an inhibitor to 
prevent that interaction, we could prevent the virus from 
spreading. It’s called ‘host-directed therapeutics.’”
But his lab isn’t focused on rabies for rabies’ sake.
Dr. Harty and colleagues are using what they learn from 
the rabies virus to apply it to other viruses that assemble and 
bud similarly, like Ebola and Marburg and other hemorrhagic 
syndrome viruses.
“Ebola and rabies viruses, they bud similarly,” said Dr. 
Harty. “So if you find the inhibitor to block one, you could 
block many others.”
Those others include HIV, Marburg and arenaviruses, such 
as Lassa fever.
Some of these viruses are considered likely bioterrorism 
agents and are on the high priority list of the Center for 
Disease Control and National Institutes of Health. High 
priority agents pose a risk to national security because they 
can be easily disseminated or transmitted, have potential for 
major public health impact and could cause widespread panic.
If Dr. Harty’s lab can understand the mechanism of virus 
budding, then candidate drugs can be identified and presented 
to slow down the assembly/budding process and give the 
immune system an opportunity to begin fighting the pathogen. 
“Vet schools are on the front line in terms of identifying 
and combating pathogens,” said Dr. Harty. “Many diseases 
are zoonotic in origin so if we can understand how a virus 
works we can more quickly act if and when it jumps to the 
human population.”
solVing the MrsA Mystery
Methicillin-resistant 
Staphylococcus aureus 
(MRSA) infections are 
caused by a strain of 
staph bacteria that does 
not respond well to the 
kinds of antibiotic drugs 
normally used to treat 
them. Because of that, 
they can be particularly 
challenging to the 
human doctors trying 
to treat a patient and 
frustrating and painful 
for the patient. 
If left untreated, 
superficial MRSA 
infections (of the skin 
and soft tissues) can 
progress to cause potentially life-threatening infections in a 
person’s bones, joints, bloodstream and lungs. 
So, when a MRSA scare strikes, public health experts and 
human physicians are called in to contain hysteria. People 
are told to wash their hands well and often, keep wounds 
covered, shower after working out and keep sheets on their 
beds clean. 
But in some cases, the cycle – and the infection – 
continues, leaving patients and doctors confused and 
concerned. 
diagram showing the sequential steps of rabies virus budding.   
The rabies virus M protein directs the early assembly process 
of viral RNA and associated proteins (N protein) at sites on the 
inner surface of the plasma membrane that are enriched for 
the G surface protein. packaging of the helical viral RNA/protein 
complex into the virus particles begins as does bud protrusion 
through the plasma membrane. Host proteins recruited by 
the viral M protein help to facilitate the final step of virus-cell 
separation or pinching-off from cell surface, leading to the release 
and dissemination of mature, infectious virions. (Figure designed 
and created by Deborah Argento).  
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Dr. Harty at work in his lab.
Dr. Morris evaluating a patient at 
Ryan Hospital.
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And it’s when he hears about cases like these that Daniel 
O. Morris, DVM, MPH, section chief of dermatology and 
allergy at Ryan Hospital and professor of dermatology, brings 
a different point of view to the table. 
“When a person has contracted a drug-resistant staph 
infection, you have to look at the entire household,” said  
Dr. Morris. “You have to ask the human patient, ‘Do you 
have any pets?’” 
Pets are, according to Dr. Morris, a potential link in 
the cycle of infections within a household. Although pets 
typically carry a different species of Staph bacteria than do 
people, they are still capable of becoming silent carriers of 
the MRSA bacteria, just like their human counterparts. They 
can also develop MRSA infections, but their role in passing 
infections back to people is poorly characterized at the 
present time.    
It’s that potential link – of pets passing infections back to 
people – that Dr. Morris, in conjunction with the Perelman 
School of Medicine and Johns Hopkins, is looking at in a 
recently launched study. In it, Dr. Morris and his human 
medicine colleagues are specifically examining the prevalence 
of MRSA bacteria on pets and their bedding in households 
where a family member has a recurring MRSA infection. 
The study will also assess the persistence of Staph carriage 
by the pet, when the household and family members 
undergo a treatment intervention. It’s an important step in 
understanding the relationships between people and their pets 
and the appropriateness of how close we should allow our 
best friends to be. 
In the case of a recurring infection, is the person living 
with a pet? And is the pet sleeping in the bed? Giving kisses? 
Is the pet a dog that serves in a therapy capacity and goes on 
hospital visits, where the likelihood of contracting MRSA is 
greater? If so, and the pet is a “silent carrier,” the recurring 
infection of a household member could potentially be related 
to close pet contact, and this relationship will need to be 
adjusted to put an end to the cycle.
But just the simple question of “Do you own a dog?” isn’t 
often in a medical doctor’s repertoire.  
“Veterinarians need to be involved when a physician 
suggests a pet-to-person link,” said Dr. Morris. “It’s what 
they do. They’re trained to ask different questions and they 
understand the human-animal bond a little better than a 
medical doctor might. The pet is the member of the family 
– they’re sleeping in the same bed, licking people’s faces. It’s 
what’s in the journals we read and it’s what we talk about as 
part of our daily practice.” 
defining diseAse bioMArkers
Cutaneous leishmaniasis is an ugly disease. A protozoan 
parasite transmitted by sand flies, leishmaniasis may not sound 
familiar to many in the U.S., but for the people of Brazil 
and across the Middle East 
and Afghanistan, the disease 
is much more prevalent. In 
Corte de Pedra, Brazil there are 
approximately 1,000 new cases 
annually.
And it is there that Phillip 
Scott, PhD, associate dean 
for research, professor of 
microbiology and immunology, 
focuses his research. 
There are two types of 
the parasite – cutaneous and 
visceral. Dr. Scott’s lab focuses on the cutaneous disease, 
which causes skin lesions, hair loss and dermatitis. The 
parasite affects people, as well as dogs. 
“It’s similar to leprosy,” said Dr. Scott. 
(The visceral type leads to swollen lymph nodes, weight 
loss, decreased appetite, nose bleeds and, eventually, kidney 
failure.) 
What is interesting about the cutaneous disease is that 
some individuals have a severe reaction to infection while 
others have more mild reactions. 
In his laboratory, Dr. Scott and his colleagues are working 
to define biomarkers to understand this discrepancy in 
reaction. Based on an individual’s immune response, his lab 
may be able to successfully fight infection with the help of a 
drug, while others may need repeated treatments. 
When early lesions are identified, an individual 
goes through a 21-day treatment of receiving the drug 
intravenously. 
If however, within the first 15 days of infection, a 
biomarker is identified that shows a person will not respond 
to that treatment, the attending physician can jump straight 
to the second treatment option, which involves a stronger, 
more expensive drug. 
“There’s no vaccine, treatment isn’t great,” said Dr. 
Scott, “but if we can identify the biomarkers of those people 
who don’t respond well with the traditional first round of 
treatment, we can go straight to the second option – a better, 
more expensive drug.”
In a recent paper published in The Journal of Immunology, 
Dr. Scott and co-investigators point out a probable link 
between the relationship of T cell response and the 
likelihood of the cutaneous lesions returning. That is, the 
inability of lymph nodes to recruit lymphocytes may mean a 
greater likelihood of a chronic, recurring condition in certain 
individuals. 
“Understanding how these parasites circumvent generating 
a strong immune response allows us to design new therapies 
to enhance immune responses in patients, and thus promote 
more rapid cure of the disease,” said Dr. Scott. 
phillip Scott, phD
